Atypical COL3A1 variants (glutamic acid to lysine) cause vascular Ehlers–Danlos syndrome with a consistent phenotype of tissue fragility and skin hyperextensibility

Article metrics

Abstract

Purpose

The Ehlers–Danlos syndromes (EDS) are a group of rare inherited connective tissue disorders. Vascular EDS (vEDS) is caused by pathogenic variants in COL3A1, most frequently glycine substitutions. We describe the phenotype of the largest series of vEDS patients with glutamic acid to lysine substitutions (Glu>Lys) in COL3A1, which were all previously considered to be variants of unknown significance.

Methods

Clinical and molecular data for seven families with three different Glu>Lys substitutions in COL3A1 were analyzed.

Results

These Glu>Lys variants were reclassified from variants of unknown significance to either pathogenic or likely pathogenic in accordance with American College of Medical Genetics and Genomics guidelines. All individuals with these atypical variants exhibited skin hyperextensibility as seen in individuals with classical EDS and classical-like EDS and evidence of tissue fragility as seen in individuals with vEDS.

Conclusion

The clinical data demonstrate the overlap between the different EDS subtypes and underline the importance of next-generation sequencing gene panel analysis. The three different Glu>Lys variants point toward a new variant type in COL3A1 causative of vEDS, which has consistent clinical features. This is important knowledge for COL3A1 variant interpretation. Further follow-up data are required to establish the severity of tissue fragility complications compared with patients with other recognized molecular causes of vEDS.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:8–26.

  2. 2.

    Malfait F Vascular aspects of the Ehlers-Danlos syndromes. Matrix Biol. 2018;71–72:380–395.

  3. 3.

    Supertifurga A, Steinmann B, Ramirze F, Byers PH. Molecular defects of type-3 collagen in Ehlers-Danlos syndrome type-4. Collagen Rel Res. 1988;8:509–509.

  4. 4.

    Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175:40–47.

  5. 5.

    Chiarelli N, Carini G, Zoppi N, Ritelli M, Colombi M. Transcriptome analysis of skin fibroblasts with dominant negative COL3A1 mutations provides molecular insights into the etiopathology of vascular Ehlers-Danlos syndrome. PLoS One. 2018;13:e0191220.

  6. 6.

    Leistritz DF, Pepin MG, Schwarze U, Byers PH. COL3A1 haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy. Genet Med. 2011;13:717–722.

  7. 7.

    Schwarze U, Schievink WI, Petty E, et al. Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV. Am J Hum Genet. 2001;69:989–1001.

  8. 8.

    Frank M, Albuisson J, Ranque B, et al. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome. Eur J Hum Genet. 2015;23:1657–1664.

  9. 9.

    Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). Genet Med. 2014;16:881–888.

  10. 10.

    Bowen JM, Sobey GJ, Burrows NP, et al. Ehlers-Danlos syndrome, classical type. Am J Med Genet C Semin Med Genet. 2017;175:27–39.

  11. 11.

    Symoens S, Syx D, Malfait F, et al. Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with classic EDS and allows to refine diagnostic criteria. Hum Mutat. 2012;33:1485–1493.

  12. 12.

    Colombi M, Dordoni C, Venturini M, Zanca A, Calzavara-Pinton P, Ritelli M. Delineation of Ehlers-Danlos syndrome phenotype due to the c.934C>T, p.(Arg312Cys) mutation in COL1A1: report on a three-generation family without cardiovascular events, and literature review. Am J Med Genet A. 2017;173:524–530.

  13. 13.

    Malfait F, Symoens S, De Backer J, et al. Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. Hum Mutat. 2007;28:387–395.

  14. 14.

    Gaines R, Tinkle BT, Halandras PM, Al-Nouri O, Crisostomo P, Cho JS. Spontaneous ruptured dissection of the right common iliac artery in a patient with classic Ehlers-Danlos syndrome phenotype. Ann Vasc Surg. 2015;29:595 e511–594.

  15. 15.

    Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet. 1998;77:31–37.

  16. 16.

    Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.

  17. 17.

    Weerakkody RA, Vandrovcova J, Kanonidou C, et al. Targeted next-generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome. Genet Med. 2016;18:1119–1127.

  18. 18.

    Pope FM, Burrows NP. Ehlers-Danlos syndrome has varied molecular mechanisms. J Med Genet. 1997;34:400–410.

  19. 19.

    Pope FM, Narcisi P, Nicholls AC, Germaine D, Pals G, Richards AJ. COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture. Br J Dermatol. 1996;135:163–181.

  20. 20.

    Vogel A, Holbrook KA, Steinmann B, Gitzelmann R, Byers PH. Abnormal collagen fibril structure in the gravis form (type I) of Ehlers-Danlos syndrome. Lab Invest. 1979;40:201–206.

  21. 21.

    Steinmann B, Superti-Furga A, Joller-Jemelka HI, Cetta G, Byers PH. Ehlers-Danlos syndrome type IV: a subset of patients distinguished by low serum levels of the amino-terminal propeptide of type III procollagen. Am J Med Genet. 1989;34:68–71.

  22. 22.

    Beighton P, de Paepe A, Danks D, et al. International Nosology of Heritable Disorders of Connective Tissue, Berlin, 1986. Am J Med Genet. 1988;29:581–594.

  23. 23.

    Dermnet New Zealand. Bleeding and bruising. https://www.dermnetnz.org/topics/bleeding-and-bruising/. Accessed 4 December 2018.

  24. 24.

    D'Hondt S, Van Damme T, Malfait F. Vascular phenotypes in nonvascular subtypes of the Ehlers-Danlos syndrome: a systematic review. Genet Med. 2018;20:562–573.

  25. 25.

    Germain DP. Ehlers-Danlos syndrome type IV. Orphanet J Rare Dis. 2007;2:32.

  26. 26.

    Beighton P. Lethal complications of the Ehlers-Danlos syndrome. Br Med J. 1968;3:656–659.

  27. 27.

    De Paepe A, Nicholls A, Narcisi P, et al. Ehlers-Danlos syndrome type I: a clinical and ultrastructural study of a family with reduced amounts of collagen type III. Br J Dermatol. 1987;117:89–97.

  28. 28.

    Nuytinck L, Freund M, Lagae L, Pierard GE, Hermanns-Le T, De Paepe A. Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen. Am J Hum Genet. 2000;66:1398–1402.

  29. 29.

    Ritelli M, Dordoni C, Venturini M, et al. Clinical and molecular characterization of 40 patients with classic Ehlers-Danlos syndrome: identification of 18 COL5A1 and 2 COL5A2 novel mutations. Orphanet J Rare Dis. 2013;8:58.

  30. 30.

    Stembridge NS, Vandersteen AM, Ghali N, et al. Clinical, structural, biochemical and X-ray crystallographic correlates of pathogenicity for variants in the C-propeptide region of the COL3A1 gene. Am J Med Genet A. 2015;167A:1763–1772.

  31. 31.

    Demirdas S, Dulfer E, Robert L, et al. Recognizing the tenascin-X deficient type of Ehlers-Danlos syndrome: a cross-sectional study in 17 patients. Clin Genet. 2017;91:411–425.

  32. 32.

    Besselink-Lobanova A, Maandag NJ, Voermans NC, van der Heijden HF, van der Hoeven JG, Heunks LM. Trachea rupture in tenascin-X-deficient type Ehlers-Danlos syndrome. Anesthesiology. 2010;113:746–749.

  33. 33.

    Sakiyama T, Kubo A, Sasaki T, et al. Recurrent gastrointestinal perforation in a patient with Ehlers-Danlos syndrome due to tenascin-X deficiency. J Dermatol. 2015;42:511–514.

  34. 34.

    Blackburn PR, Xu Z, Tumelty KE, et al. Bi-allelic alterations in AEBP1 lead to defective collagen assembly and connective tissue structure resulting in a variant of Ehlers-Danlos syndrome. Am J Hum Genet. 2018;102:696–705.

  35. 35.

    Persikov AV, Ramshaw JA, Brodsky B. Prediction of collagen stability from amino acid sequence. J Biol Chem. 2005;280:19343–19349.

  36. 36.

    Raynal N, Hamaia SW, Siljander PR, et al. Use of synthetic peptides to locate novel integrin alpha2beta1-binding motifs in human collagen III. J Biol Chem. 2006;281:3821–3831.

  37. 37.

    Parkin JD, San Antonio JD, Persikov AV, et al. The collalphagen III fibril has a “flexi-rod” structure of flexible sequences interspersed with rigid bioactive domains including two with hemostatic roles. PLoS One. 2017;12:e0175582.

  38. 38.

    Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342:673–680.

  39. 39.

    Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376:1476–1484.

Download references

Acknowledgements

We express our gratitude to all the families who participated in the study. We thank Tim Aitman and Ruwan Weerakkody for the sequencing and research data for family 2 and family 4.

Author information

Correspondence to Neeti Ghali MD.

Ethics declarations

Disclosure

The authors declare no conflicts of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary InformationIII

Supplementary InformationI

Supplementary InformationII

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Ehlers–Danlos syndrome
  • COL3A1
  • vascular EDS
  • glutamic acid to lysine substitutions